Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $47.6 million.

  • Seres Therapeutics' Cash & Equivalents fell 2871.12% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year decrease of 2871.12%. This contributed to the annual value of $30.8 million for FY2024, which is 7593.64% down from last year.
  • As of Q3 2025, Seres Therapeutics' Cash & Equivalents stood at $47.6 million, which was down 2871.12% from $45.4 million recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Cash & Equivalents ranged from a high of $353.2 million in Q3 2021 and a low of $30.8 million during Q4 2024
  • Over the past 5 years, Seres Therapeutics' median Cash & Equivalents value was $163.0 million (recorded in 2022), while the average stood at $154.2 million.
  • As far as peak fluctuations go, Seres Therapeutics' Cash & Equivalents surged by 39683.54% in 2021, and later plummeted by 7593.64% in 2024.
  • Over the past 5 years, Seres Therapeutics' Cash & Equivalents (Quarter) stood at $180.0 million in 2021, then fell by 9.43% to $163.0 million in 2022, then decreased by 21.51% to $128.0 million in 2023, then tumbled by 75.94% to $30.8 million in 2024, then skyrocketed by 54.7% to $47.6 million in 2025.
  • Its last three reported values are $47.6 million in Q3 2025, $45.4 million for Q2 2025, and $58.8 million during Q1 2025.